Aspen is now also considering the possibility of an initial public offering next year in an effort to bring its cell therapy ...
Roche RHHBY announced that it will advance pipeline candidate prasinezumab into phase III development for early-stage Parkinson’s disease. Roche has a licensing agreement with Prothena PRTA for ...
Stocktwits on MSN
Annovis Stock Rises After Company Confirms Meeting With Regulators To Discuss Drug In Treating Parkinson's Disease Dementia
The January meeting is intended to discuss the clinical trial design, patient population, and a potential approval route for ...
Detailed price information for Annovis Bio Inc (ANVS-N) from The Globe and Mail including charting and trades.
Buntanetap significantly improves cognition in all Parkinson’s patients, with those exhibiting Alzheimer’s co-pathology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback